Cargando…

S-phase–specific radiosensitization by gemcitabine for therapeutic carbon ion exposure in vitro

Densely ionizing charged particle irradiation offers physical as well as biological advantages compared with photon irradiation. Radiobiological data for the combination of such particle irradiation (i.e. therapeutic carbon ions) with commonly used chemotherapeutics are still limited. Recent in vitr...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrabi, Semi B., Adeberg, Sebastian, Winter, Marcus, Haberer, Thomas, Debus, Jürgen, Weber, Klaus-Josef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4795954/
https://www.ncbi.nlm.nih.gov/pubmed/26747201
http://dx.doi.org/10.1093/jrr/rrv097
_version_ 1782421690512310272
author Harrabi, Semi B.
Adeberg, Sebastian
Winter, Marcus
Haberer, Thomas
Debus, Jürgen
Weber, Klaus-Josef
author_facet Harrabi, Semi B.
Adeberg, Sebastian
Winter, Marcus
Haberer, Thomas
Debus, Jürgen
Weber, Klaus-Josef
author_sort Harrabi, Semi B.
collection PubMed
description Densely ionizing charged particle irradiation offers physical as well as biological advantages compared with photon irradiation. Radiobiological data for the combination of such particle irradiation (i.e. therapeutic carbon ions) with commonly used chemotherapeutics are still limited. Recent in vitro results indicate a general prevalence of additive cytotoxic effects in combined treatments, but an extension of established multimodal treatment regimens with photons to the inclusion of particle therapy needs to evaluate possible peculiarities of using high linear energy transfer (LET) radiation. The present study investigates the effect of combined radiochemotherapy using gemcitabine and high-LET irradiation with therapeutic carbon ions. In particular, the earlier observation of S-phase specific radiosensitization with photon irradiation should be evaluated with carbon ions. In the absence of the drug gemcitabine, carbon ion irradiation produced the typical survival behavior seen with X-rays—increased relative biological efficiency, and depletion of the survival curve's shoulder. By means of serum deprivation and subsequent replenishment, ∼70% S-phase content of the cell population was achieved, and such preparations showed radioresistance in both treatment arms—,photon and carbon ion irradiation. Combined modality treatment with gemcitabine caused significant reduction of clonogenic survival especially for the S-phase cells. WIDR cells exhibited S-phase–specific radioresistance with high-LET irradiation, although this was less pronounced than for X-ray exposure. The combined treatment with therapeutic carbon ions and gemcitabine caused the resistance phenomenon to disappear phenotypically.
format Online
Article
Text
id pubmed-4795954
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-47959542016-03-21 S-phase–specific radiosensitization by gemcitabine for therapeutic carbon ion exposure in vitro Harrabi, Semi B. Adeberg, Sebastian Winter, Marcus Haberer, Thomas Debus, Jürgen Weber, Klaus-Josef J Radiat Res Radiation Biology Densely ionizing charged particle irradiation offers physical as well as biological advantages compared with photon irradiation. Radiobiological data for the combination of such particle irradiation (i.e. therapeutic carbon ions) with commonly used chemotherapeutics are still limited. Recent in vitro results indicate a general prevalence of additive cytotoxic effects in combined treatments, but an extension of established multimodal treatment regimens with photons to the inclusion of particle therapy needs to evaluate possible peculiarities of using high linear energy transfer (LET) radiation. The present study investigates the effect of combined radiochemotherapy using gemcitabine and high-LET irradiation with therapeutic carbon ions. In particular, the earlier observation of S-phase specific radiosensitization with photon irradiation should be evaluated with carbon ions. In the absence of the drug gemcitabine, carbon ion irradiation produced the typical survival behavior seen with X-rays—increased relative biological efficiency, and depletion of the survival curve's shoulder. By means of serum deprivation and subsequent replenishment, ∼70% S-phase content of the cell population was achieved, and such preparations showed radioresistance in both treatment arms—,photon and carbon ion irradiation. Combined modality treatment with gemcitabine caused significant reduction of clonogenic survival especially for the S-phase cells. WIDR cells exhibited S-phase–specific radioresistance with high-LET irradiation, although this was less pronounced than for X-ray exposure. The combined treatment with therapeutic carbon ions and gemcitabine caused the resistance phenomenon to disappear phenotypically. Oxford University Press 2016-03 2016-01-07 /pmc/articles/PMC4795954/ /pubmed/26747201 http://dx.doi.org/10.1093/jrr/rrv097 Text en © The Author 2016. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Radiation Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Radiation Biology
Harrabi, Semi B.
Adeberg, Sebastian
Winter, Marcus
Haberer, Thomas
Debus, Jürgen
Weber, Klaus-Josef
S-phase–specific radiosensitization by gemcitabine for therapeutic carbon ion exposure in vitro
title S-phase–specific radiosensitization by gemcitabine for therapeutic carbon ion exposure in vitro
title_full S-phase–specific radiosensitization by gemcitabine for therapeutic carbon ion exposure in vitro
title_fullStr S-phase–specific radiosensitization by gemcitabine for therapeutic carbon ion exposure in vitro
title_full_unstemmed S-phase–specific radiosensitization by gemcitabine for therapeutic carbon ion exposure in vitro
title_short S-phase–specific radiosensitization by gemcitabine for therapeutic carbon ion exposure in vitro
title_sort s-phase–specific radiosensitization by gemcitabine for therapeutic carbon ion exposure in vitro
topic Radiation Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4795954/
https://www.ncbi.nlm.nih.gov/pubmed/26747201
http://dx.doi.org/10.1093/jrr/rrv097
work_keys_str_mv AT harrabisemib sphasespecificradiosensitizationbygemcitabinefortherapeuticcarbonionexposureinvitro
AT adebergsebastian sphasespecificradiosensitizationbygemcitabinefortherapeuticcarbonionexposureinvitro
AT wintermarcus sphasespecificradiosensitizationbygemcitabinefortherapeuticcarbonionexposureinvitro
AT habererthomas sphasespecificradiosensitizationbygemcitabinefortherapeuticcarbonionexposureinvitro
AT debusjurgen sphasespecificradiosensitizationbygemcitabinefortherapeuticcarbonionexposureinvitro
AT weberklausjosef sphasespecificradiosensitizationbygemcitabinefortherapeuticcarbonionexposureinvitro